TICKERNERD
Menu
RCKTRCKTHealthcare · Biotechnology

RCKT Stock Forecast: Rocket Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$3.53
+0.57% on the day

The 14 Wall Street analysts covering Rocket Pharmaceuticals, Inc. hold a median 12-month price target of $10 — +183.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 52 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$385.3M
Ticker Nerd rank
52 / 100
Median analyst target
$10
Analysts covering
14
Revenue$0.0
Operating income−$48.5M
Net income−$47.6M
Free cash flow−$45.5M
Quarterly, 8 quarters to 31 Mar 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+3.8%
1M
+10.7%
YTD
+0.6%
1Y
−3.0%
From 52W high
−33.4%
From 52W low
+35.8%
$2.60
$5.30
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RCKT stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rocket Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
52 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
82
Revisions
62
Quality
60
Size
58
Issuance
50
Value
46
Volatility
41
Accruals
39
Momentum
27

Growth (82): Sales and profits are climbing, and climbing faster than before.

Momentum (27): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RCKT stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RCKT, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26RCKTHigh $15Median $10Low $3

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says14 analysts
6 Buy6 Hold2 Sell
Low $3Median $10High $15

The green dot is the last close — the median target sits +183.3% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
11 Aug 2026WedbushMaintainsOutperform$16 → $15
11 May 2026Chardan CapitalMaintainsBuy$11
11 May 2026Chardan CapitalMaintainsBuy—
30 Mar 2026B of A SecuritiesMaintainsBuy—
27 Mar 2026Chardan CapitalMaintainsBuy—
2 Mar 2026Goldman SachsMaintainsSell—
27 Feb 2026Cantor FitzgeraldMaintainsOverweight—
18 Nov 2025B of A SecuritiesMaintainsBuy—
18 Nov 2025JP MorganDowngradeUnderweight—
14 Oct 2025Chardan CapitalMaintainsBuy—
3 Oct 2025Leerink PartnersMaintainsMarket Perform—
20 Aug 2025B of A SecuritiesUpgradeBuy—
20 Aug 2025Chardan CapitalMaintainsBuy—
11 Aug 2025Chardan CapitalMaintainsBuy—
8 Aug 2025Cantor FitzgeraldMaintainsOverweight—
25 July 2025B of A SecuritiesDowngradeNeutral—
25 July 2025Canaccord GenuityMaintainsBuy—
24 July 2025Chardan CapitalMaintainsBuy—
24 July 2025NeedhamMaintainsHold—
17 June 2025UBSMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RCKT appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RCKT vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Rocket Pharmaceuticals, Inc. returned −3.0% against +19.6% for the S&P 500, dividends included.

RCKT vs S&P 500, last 12 monthsTotal return, rebased to 100
80100120140160Oct 25Jan 26Apr 26Jul 26RCKTS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RCKT analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
1
Fundamentals

Rocket Pharmaceuticals, Inc. (RCKT) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.7×

Cheaper than 84% of US stocks

Price / sales
—
Price / book
1.6×

Cheaper than 54% of US stocks

EV / EBITDA
−0.7×

Cheaper than 64% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−4.8%

Higher than 39% of US stocks

Return on assets
−28.4%

Higher than 15% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rocket Pharmaceuticals, Inc. (RCKT) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rocket Pharmaceuticals, Inc. has a market value of $385.3M and an enterprise value of $126.4M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$209.4M.

  • Diluted earnings per share, trailing twelve months: $−1.87.

  • Free cash flow in the twelve months to 31 Mar 2026: −$179.8M, after $169K of capital spending.

  • Shares outstanding: 109.1M.

  • Trailing P/E: −1.7×; forward P/E: −2.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Rocket Pharmaceuticals, Inc. employs 202 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

RCKT vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RCKTRocket Pharmaceuticals, Inc.$385.3M
52
LYELLyell Immunopharma, Inc.$380.6M
65
UPBUpstream Bio, Inc.$381.8M
31
ARCTArcturus Therapeutics Holdings, Inc.$382.1M
61
LXEOLexeo Therapeutics, Inc.$383.2M
31
IPSCCentury Therapeutics, Inc.$371.9M
39
ENTAEnanta Pharmaceuticals, Inc.$388.6M
87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rocket Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RCKT news & analysis

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

Zacks Investment Research · 11 Aug 2026positive

Rocket Pharmaceuticals recorded earnings growth in the second quarter. Kresladi launch preparations are advancing, and safety findings for RP-A501 support its next development steps.

Why it matters — A RCKT watcher would care because the quarterly earnings growth and continued progress on both the Kresladi launch and the RP-A501 program reflect ongoing advancement across the company's pipeline.

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

Business Wire · 10 Aug 2026positive

Rocket Pharmaceuticals reported its financial results and recent operational progress for the second quarter ended June 30, 2026. The company highlighted the approval of KRESLADI, which it said materially strengthened its position and demonstrated its ability to advance a genetic medicine.

Why it matters — RCKT watchers would care because the KRESLADI approval signals significant progress for the company's genetic medicines pipeline and its commercial-stage status.

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

Benzinga · 3 Aug 2026positive

Rocket Pharmaceuticals shared a clinical safety update regarding the first three patients treated in its global, pivotal Phase 2 trial for Danon disease. The update was presented as positive early safety data from the revised genetic therapy trial.

Why it matters — RCKT watchers would care because early safety results from the pivotal Phase 2 Danon disease trial are a key data point for the company's lead genetic therapy program.

Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease

Business Wire · 3 Aug 2026positive

Rocket Pharmaceuticals announced a positive clinical safety update on the initial three patients treated with RP-A501 under the modified protocol in its global pivotal Phase 2 trial for Danon disease, with early safety showing promising results.

Why it matters — This update offers early favorable safety signals for RP-A501, a key pipeline candidate in Rocket's gene therapy program targeting Danon disease.

FAQ

Frequently asked questions about RCKT stock

What is the RCKT stock price forecast for 2026-2027?

The 14 Wall Street analysts covering Rocket Pharmaceuticals, Inc. have a median 12-month price target of $10, with estimates ranging from $3 to $15. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RCKT stock a buy right now?

Of the 14 analysts covering Rocket Pharmaceuticals, Inc., 6 rate it a Buy, 6 a Hold and 2 a Sell. Ticker Nerd's systematic factor model ranks Rocket Pharmaceuticals, Inc. 52 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RCKT?

As at 22 Aug 2026, Rocket Pharmaceuticals, Inc. ranks 52 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (82 of 100).

Will RCKT stock go up?

No one can know that. What the data says: the median 12-month target from 14 analysts implies +183.3% from the last close, and Ticker Nerd's factor model ranks Rocket Pharmaceuticals, Inc. 52 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RCKT stock forecast for 2030?

No analyst covering Rocket Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RCKT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $3 to $15 over the next 12 months.

How has RCKT stock performed over the past year?

Rocket Pharmaceuticals, Inc. returned -3.0% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rocket Pharmaceuticals, Inc. do?

Rocket Pharmaceuticals Inc. is a late-stage biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.

What is the latest news on RCKT?

The most recent item we track (Zacks Investment Research, 11 Aug 2026): "Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus". Rocket Pharmaceuticals recorded earnings growth in the second quarter. Kresladi launch preparations are advancing, and safety findings for RP-A501 support its next development steps.

Company

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals Inc. is a late-stage biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases. The company employs a multi-platform approach utilizing both adeno-associated viral (AAV) and lentiviral vector (LV) technologies to address genetic disorders with significant unmet medical needs. Its pipeline includes investigational therapies targeting conditions such as Danon disease, Fanconi Anemia, Leukocyte Adhesion Deficiency-I, Pyruvate Kinase Deficiency, and arrhythmogenic cardiomyopathy. The company has established partnerships with leading academic institutions, children's hospitals, and research centers worldwide to advance its clinical programs. Rocket maintains strategic collaborations with organizations including Children's Hospital of Philadelphia, Fred Hutchinson Cancer Research Center, and multiple universities to support the development and validation of its gene therapy candidates. Headquartered in Cranbury, New Jersey, and founded in 2015, Rocket Pharmaceuticals operates with a mission to seek gene therapy cures that address the root causes of genetic diseases, aiming to transform treatment paradigms for rare pediatric conditions.

CEO Dr. Gaurav D. Shah M.D. · 202 employees · United States · https://www.rocketpharma.com